Patient input is critical to an orphan drug’s success - from understanding the patient journey through better clinical trial design to post-launch support initiatives, patients are essential and knowledgeable partners for Pharma.
For years now the World Orphan Drugs Congress Europe has been a strong advocate of inviting and funding as many patient groups as possible, by partnering with EURORDIS and NORD and investing in fully subsidising their conference tickets, food and drink each year to help them attend the event.
To increase their participation further we are offering the chance for a number of interested Pharma companies to become “Patient Group Supporters” at the 2019 event, to show your commitment to involving patient groups throughout the drug development lifecycle.
Contributing as a Patient Group Supporter your investment will go directly towards helping the patient groups costs incurred for accommodation at the event (all funds go back into supporting patients), where we will also have a dedicated supporter lunch on one of the days where you will get to meet those who you have helped be there. A great opportunity to be seen as actively championing and working with the industries Patient Groups.
The Patient Group Sponsor opportunity includes: